[Image from Jp Valery on Unsplash]
Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.
Here are the 10 biggest mergers and acquisitions in medtech in 2021:
Next>>
The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen.
MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to end the week before last (April 9). Having only set its previous all-time best of 110.96 on Feb. 15, the industry’s topsy-turvy run gave no indication of which direction it was heading next.
However, after the rise over the past couple of weeks, the industry rode that wave to a new all-time high of 112.25 to end last week on April 16. That represents a 2.6% rise from the previous week’s tally.
Improvements continue to shine a light on the strong position the industry has settled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 21.6% rise from the pre-pandemic high of 92.32 (set on Feb. 1…
DiaSorin announced that it agreed to acquire Luminex in an all-cash transaction worth approximately $1.8 billion.
Saluggia, Italy-based DiaSorin’s purchase at $37 per share of Luminex represents a 23.1% premium to Luminex shareholders based on the unaffected closing stock price of the company on Feb. 24, 2021, which was the date prior to press rumors regarding a potential sale, according to a news release. The transaction is expected to close in the third quarter of this year, subject to Luminex shareholder approval.
Luminex develops diagnostic testing products, including platforms based on multiplexing technology. The Austin, Texas-based company’s diagnostics include COVID-19 tests, which received FDA emergency use authorization last year.
DiaSorin, a diagnostics company itself, said in the release that the purchase will broaden its positioning in the molecular diagnostics space while strengthening its existing value proposition in line with…
For the third time in the past four weeks, stocks within the medtech industry climbed to never-before-seen heights as 2021 reared its head.
Previous highs have largely been a result of the FDA granting Moderna emergency use authorization for its vaccine candidate and its subsequent rollout to the U.S., joining the one made by Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX), which began to be administered last month.
With the industry plugging along, MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 104.67 (Jan. 1), marking its highest-ever total and a 1% uptick from the 103.63 points registered at the end of the week prior (Dec. 25, 2020).
A slight downturn came after the index hit a new high (100.75) on Dec. 4, 2020, beating the mark of 100.65 set on Nov. 9 and setting a new all-time high since the index started being recorded on Jan. 1, 2001. However, stocks have continued to rise …
(Image from Mayo Clinic)
Months into the pandemic, the FDA continues to grant emergency use approval (EUA) to new tests to detect the virus that causes COVID-19 and the antibodies that indicate a person has had it.
To date, the FDA has granted EUAs for 171 tests —142 molecular tests, 27 antibody tests, and 2 antigen tests. Given the ever-changing landscape of tests for COVID-19 and the rapid rise of coronavirus cases in the parts of the country, we thought an overview of these tests might be helpful.
Get the full story on our sister site, Medical Design & Outsourcing.